SG/PUT/ELI LILLY & CO/450/0.1/20.09.24 | Delayed Deutsche Boerse AG 17:54:11 03/06/2024 BST | ||
| 0.001 EUR | 0.00% |
|
| 3 months | -99.60% | ||
| 6 months | -99.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 0.001 | 0.00% |
| 31/05/24 | 0.001 | 0.00% |
| 30/05/24 | 0.001 | 0.00% |
| 29/05/24 | 0.001 | 0.00% |
| 28/05/24 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 05:54 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SV6QVQ |
| ISIN | DE000SV6QVQ7 |
| Date issued | 24/05/2023 |
| Strike | 450 $ |
| Maturity | 20/09/2024 (109 Days) |
| Parity | 10 : 1 |
| Emission price | 5.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.17 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.169 € |
| Spread % | 99.41% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Warrants
- Warrant
